{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:14:57Z","timestamp":1793970897101,"version":"4.8.0"},"reference-count":70,"publisher":"American Society of Hematology","issue":"18","license":[{"start":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9,24]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Castleman disease (CD) encompasses a spectrum of rare disorders, including unicentric CD (UCD), idiopathic multicentric CD (iMCD), and human herpesvirus 8\u2013associated MCD (HHV8+ MCD). We performed a systematic review of publications reporting \u22655 cases of CD between 1995 and 2021, following preferred reporting items for systematic reviews and meta-analyses guidelines, to describe and compare subtypes. We extracted data on clinical symptoms and laboratory parameters as stated in international consensus diagnostic criteria for iMCD and estimated the frequency of each criterion using meta-analyses. We analyzed 32 studies describing 559 UCD, 1023 iMCD, and 416 HHV8+ MCD cases. Although many symptoms and laboratory abnormalities occurred at similar rates in patients with iMCD and HHV8+ MCD, patients with HHV8+ MCD had significantly higher rates of constitutional symptoms (46.6% vs 98.6%; P\u00a0=\u00a0.038) and splenomegaly (48.2% vs 89.2%; P\u00a0=\u00a0.031). Renal dysfunction was significantly more common in patients with iMCD than in patients with HHV8+ MCD before adjustment (36.9% vs 17.4%; P\u00a0=\u00a0.04; adjusted P\u00a0=\u00a0.1). Patients with UCD had lower rates of symptoms and laboratory abnormalities, although these were present in 20% of patients and were particularly pronounced in pediatric UCD. There are many similarities in the symptomatology of iMCD and HHV8+ MCD; many patients experience constitutional symptoms and organ dysfunction. Differences between these subtypes likely reflect differences in pathophysiology and\/or comorbidity burdens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013548","type":"journal-article","created":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T11:10:17Z","timestamp":1720609817000},"page":"4924-4935","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":48,"title":["The clinical picture of Castleman disease: a systematic review and meta-analysis"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1082-8093","authenticated-orcid":false,"given":"Christian","family":"Hoffmann","sequence":"first","affiliation":[{"name":"1Infektionsmedizinisches Centrum Hamburg Study Center, Hamburg, Germany"},{"name":"2Department of Medicine, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8588-7138","authenticated-orcid":false,"given":"Eric","family":"Oksenhendler","sequence":"additional","affiliation":[{"name":"3Department of Clinical Immunology, H\u00f4pital Saint-Louis, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Littler","sequence":"additional","affiliation":[{"name":"4Select Statistical Services, Exeter, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Grant","sequence":"additional","affiliation":[{"name":"5TVF Communications, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karan","family":"Kanhai","sequence":"additional","affiliation":[{"name":"6Medical Affairs, Recordati Pharma Ltd, Hemel Hempstead, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7367-8184","authenticated-orcid":false,"given":"David C.","family":"Fajgenbaum","sequence":"additional","affiliation":[{"name":"7Department of Medicine, Center for Cytokine Storm Treatment & Laboratory, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,9,16]]},"reference":[{"issue":"22","key":"2024092412010017500_bib1","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1182\/blood-2018-05-848671","article-title":"Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease","volume":"132","author":"Fajgenbaum","year":"2018","journal-title":"Blood"},{"issue":"12","key":"2024092412010017500_bib2","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood-2016-11-748855","article-title":"Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease","volume":"129","author":"Yu","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2024092412010017500_bib3","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/bjh.15019","article-title":"The full spectrum of Castleman disease: 273 patients studied over 20 years","volume":"180","author":"Oksenhendler","year":"2018","journal-title":"Br J Haematol"},{"issue":"12","key":"2024092412010017500_bib4","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood-2016-10-746933","article-title":"International, evidence-based consensus diagnostic criteria for HHV-8-negative\/idiopathic multicentric Castleman disease","volume":"129","author":"Fajgenbaum","year":"2017","journal-title":"Blood"},{"issue":"20","key":"2024092412010017500_bib5","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1182\/blood-2018-07-862334","article-title":"International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease","volume":"132","author":"van Rhee","year":"2018","journal-title":"Blood"},{"issue":"23","key":"2024092412010017500_bib6","doi-asserted-by":"crossref","first-page":"6039","DOI":"10.1182\/bloodadvances.2020003334","article-title":"International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease","volume":"4","author":"van Rhee","year":"2020","journal-title":"Blood Adv"},{"issue":"22","key":"2024092412010017500_bib7","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1182\/blood-2010-07-290213","article-title":"How I treat HIV-associated multicentric Castleman disease","volume":"116","author":"Bower","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2024092412010017500_bib8","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.blre.2017.11.005","article-title":"Clinical, laboratory and imaging findings in Castleman's disease \u2013 the subtype decides","volume":"32","author":"Haap","year":"2018","journal-title":"Blood Rev"},{"issue":"4","key":"2024092412010017500_bib9","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1016\/S2352-3026(16)00006-5","article-title":"Idiopathic multicentric Castleman's disease: a systematic literature review","volume":"3","author":"Liu","year":"2016","journal-title":"Lancet Haematol"},{"issue":"16","key":"2024092412010017500_bib10","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1182\/blood.2019000931","article-title":"Overview of Castleman disease","volume":"135","author":"Dispenzieri","year":"2020","journal-title":"Blood"},{"issue":"5","key":"2024092412010017500_bib11","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.3109\/10428194.2014.935368","article-title":"Human immunodeficiency virus-associated multicentric Castleman disease refractory to antiretroviral therapy: clinical features, treatment and outcome","volume":"56","author":"Alzahrani","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2024092412010017500_bib12","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/bjh.13378","article-title":"Clinical and laboratory characterization of 114 cases of Castleman disease patients from a single centre: paraneoplastic pemphigus is an unfavourable prognostic factor","volume":"169","author":"Dong","year":"2015","journal-title":"Br J Haematol"},{"issue":"7","key":"2024092412010017500_bib13","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s00432-018-2647-z","article-title":"Analysis of clinical characteristics and prognosis factors of 71 cases with HIV-negative Castleman's disease: hypoproteinemia is an unfavorable prognostic factor which should be treated appropriately","volume":"144","author":"Lan","year":"2018","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"1","key":"2024092412010017500_bib14","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/cas.13439","article-title":"Clinical characteristics and outcomes of Castleman disease: a multicenter study of 185 Chinese patients","volume":"109","author":"Zhang","year":"2018","journal-title":"Cancer Sci"},{"issue":"16","key":"2024092412010017500_bib15","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2018-11-884577","article-title":"Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease","volume":"133","author":"Zhang","year":"2019","journal-title":"Blood"},{"issue":"2","key":"2024092412010017500_bib16","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00432-019-03120-w","article-title":"Clinical features and treatment of 7 Chinese TAFRO syndromes from 96 de novo Castleman diseases: a 10-year retrospective study","volume":"146","author":"Zhang","year":"2020","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"1","key":"2024092412010017500_bib17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40644-019-0238-0","article-title":"Imaging and clinical features of Castleman disease","volume":"19","author":"Zhao","year":"2019","journal-title":"Cancer Imaging"},{"issue":"2","key":"2024092412010017500_bib18","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/bjh.15921","article-title":"Treatment and outcome of unicentric Castleman disease: a retrospective analysis of 71 cases","volume":"186","author":"Boutboul","year":"2019","journal-title":"Br J Haematol"},{"issue":"13","key":"2024092412010017500_bib19","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1182\/blood-2011-02-333633","article-title":"Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease","volume":"118","author":"Hoffmann","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2024092412010017500_bib20","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s12288-015-0602-6","article-title":"Presentation and outcome of Castleman's disease in immunocompetent hosts","volume":"32","author":"Prakash","year":"2016","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"9","key":"2024092412010017500_bib21","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/ajh.25554","article-title":"Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease?","volume":"94","author":"Fujimoto","year":"2019","journal-title":"Am J Hematol"},{"key":"2024092412010017500_bib22","doi-asserted-by":"crossref","first-page":"42316","DOI":"10.1038\/srep42316","article-title":"Elevated serum interferon gamma-induced protein 10\u00a0kDa is associated with TAFRO syndrome","volume":"7","author":"Iwaki","year":"2017","journal-title":"Sci Rep"},{"issue":"1","key":"2024092412010017500_bib23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3960\/jslrt.53.69","article-title":"Clinical features and treatment of multicentric Castleman's disease: a retrospective study of 21 Japanese patients at a single institute","volume":"53","author":"Kawabata","year":"2013","journal-title":"J\u00a0Clin Exp Hematop"},{"issue":"5","key":"2024092412010017500_bib24","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/14397595.2019.1704983","article-title":"Clinicopathologic characteristics of 342 patients with multicentric Castleman disease in Japan","volume":"30","author":"Murakami","year":"2020","journal-title":"Mod Rheumatol"},{"issue":"2","key":"2024092412010017500_bib25","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/imj.14404","article-title":"Comparison of the clinical characteristics of TAFRO syndrome and idiopathic multicentric Castleman disease in general internal medicine: a 6-year retrospective study","volume":"50","author":"Nishimura","year":"2020","journal-title":"Intern Med J"},{"issue":"4","key":"2024092412010017500_bib26","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1177\/0956462420905277","article-title":"HIV-associated multicentric Castleman disease: a report of 19 cases at an oncology institution","volume":"31","author":"Volkow-Fernandez","year":"2020","journal-title":"Int J STD AIDS"},{"issue":"suppl","key":"2024092412010017500_bib27","doi-asserted-by":"crossref","first-page":"S159","DOI":"10.1016\/j.clml.2016.03.009","article-title":"Human herpesvirus type 8-positive multicentric Castleman disease","volume":"16","author":"Melikyan","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"2024092412010017500_bib28","doi-asserted-by":"crossref","first-page":"253","DOI":"10.5045\/br.2014.49.4.253","article-title":"Clinical features and outcomes in patients with human immunodeficiency virus-negative, multicentric Castleman's disease: a single medical center experience","volume":"49","author":"Seo","year":"2014","journal-title":"Blood Res"},{"issue":"8","key":"2024092412010017500_bib29","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.3109\/10428194.2011.574759","article-title":"Clinical dissection of multicentric Castleman disease","volume":"52","author":"Shin","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"14","key":"2024092412010017500_bib30","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1080\/10428194.2019.1639168","article-title":"Clinical and pathological characteristics of Castleman disease: an observational study in a Spanish tertiary hospital","volume":"60","author":"Gonzalez-Garcia","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2024092412010017500_bib31","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1097\/QAI.0b013e3182a8338f","article-title":"Diagnostic criteria schemes for multicentric Castleman disease in 75 cases","volume":"65","author":"Bower","year":"2014","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"1","key":"2024092412010017500_bib32","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/bjh.13111","article-title":"Clinical characteristics and healthcare utilization of patients with multicentric Castleman disease","volume":"168","author":"Casper","year":"2015","journal-title":"Br J Haematol"},{"issue":"3","key":"2024092412010017500_bib33","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/1097-0142(20010801)92:3<670::AID-CNCR1369>3.0.CO;2-Q","article-title":"Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy","volume":"92","author":"Chronowski","year":"2001","journal-title":"Cancer"},{"issue":"11","key":"2024092412010017500_bib34","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/ajh.23291","article-title":"The clinical spectrum of Castleman's disease","volume":"87","author":"Dispenzieri","year":"2012","journal-title":"Am J Hematol"},{"issue":"8","key":"2024092412010017500_bib35","doi-asserted-by":"crossref","first-page":"657","DOI":"10.7326\/0003-4819-128-8-199804150-00010","article-title":"The clinical behavior of localized and multicentric Castleman disease","volume":"128","author":"Herrada","year":"1998","journal-title":"Ann Intern Med"},{"issue":"1049","key":"2024092412010017500_bib36","doi-asserted-by":"crossref","first-page":"20140670","DOI":"10.1259\/bjr.20140670","article-title":"Multimodality imaging and clinical features in Castleman disease: single institute experience in 30 patients","volume":"88","author":"Hill","year":"2015","journal-title":"Br J Radiol"},{"issue":"16","key":"2024092412010017500_bib37","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood-2019-01-893339","article-title":"Viral, immunologic, and clinical features of primary effusion lymphoma","volume":"133","author":"Lurain","year":"2019","journal-title":"Blood"},{"issue":"25","key":"2024092412010017500_bib38","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood.2019004602","article-title":"Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus-associated multicentric Castleman disease","volume":"135","author":"Ramaswami","year":"2020","journal-title":"Blood"},{"issue":"26","key":"2024092412010017500_bib39","doi-asserted-by":"crossref","first-page":"6977","DOI":"10.1182\/blood-2010-11-317610","article-title":"High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy","volume":"117","author":"Uldrick","year":"2011","journal-title":"Blood"},{"issue":"24","key":"2024092412010017500_bib40","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1182\/blood-2014-07-586800","article-title":"Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease","volume":"124","author":"Uldrick","year":"2014","journal-title":"Blood"},{"issue":"5","key":"2024092412010017500_bib41","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1309\/AJCPKGF7U8AWQBVG","article-title":"Bone marrow findings in HIV-positive patients with Kaposi sarcoma herpesvirus-associated multicentric Castleman disease","volume":"139","author":"Venkataraman","year":"2013","journal-title":"Am J Clin Pathol"},{"issue":"8","key":"2024092412010017500_bib42","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s004310051166","article-title":"Paediatric Castleman disease: report of seven cases and review of the literature","volume":"158","author":"Parez","year":"1999","journal-title":"Eur J Pediatr"},{"issue":"1","key":"2024092412010017500_bib43","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/pbc.25220","article-title":"Clinical and experimental study of Castleman disease in children","volume":"62","author":"Zhang","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"2024092412010017500_bib44","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13023-020-1345-5","article-title":"The French paediatric cohort of Castleman disease: a retrospective report of 23 patients","volume":"15","author":"Borocco","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"2024092412010017500_bib45","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/ajcp\/aqaa011","article-title":"Histologic and laboratory characteristics of symptomatic and asymptomatic Castleman disease in the pediatric population","volume":"153","author":"Chisholm","year":"2020","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"2024092412010017500_bib46","doi-asserted-by":"crossref","first-page":"e27613","DOI":"10.1002\/pbc.27613","article-title":"Castleman disease in pediatrics: insights on presentation, treatment, and outcomes from a two-site retrospective cohort study","volume":"66","author":"Sopfe","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"2024092412010017500_bib47","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1468-1293.2004.00204.x","article-title":"Castleman's disease and HIV infection in Australia","volume":"5","author":"Loi","year":"2004","journal-title":"HIV Med"},{"issue":"8","key":"2024092412010017500_bib48","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1080\/10428190903060095","article-title":"Clinical and laboratory characterization of a large cohort of patients with Castleman disease retrospectively collected from a single center","volume":"50","author":"Dong","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2024092412010017500_bib49","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12957-015-0756-6","article-title":"Clinicopathological characteristics of unicentric retroperitoneal Castleman's disease: a study of 14 cases","volume":"14","author":"Wang","year":"2016","journal-title":"World J Surg Oncol"},{"issue":"4","key":"2024092412010017500_bib50","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s12032-009-9355-0","article-title":"A\u00a0retrospective study of unicentric and multicentric Castleman's disease: a report of 52 patients","volume":"27","author":"Ye","year":"2010","journal-title":"Med Oncol"},{"issue":"1","key":"2024092412010017500_bib51","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s12032-013-0492-0","article-title":"Clinical features and outcome of patients with HIV-negative multicentric Castleman's disease treated with combination chemotherapy: a report on 10 patients","volume":"30","author":"Zhu","year":"2013","journal-title":"Med Oncol"},{"issue":"6","key":"2024092412010017500_bib52","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/cid\/cis1009","article-title":"Human herpesvirus 8-related Castleman disease in the absence of HIV infection","volume":"56","author":"Dossier","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"7","key":"2024092412010017500_bib53","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1182\/blood.V99.7.2331","article-title":"High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease","volume":"99","author":"Oksenhendler","year":"2002","journal-title":"Blood"},{"issue":"4","key":"2024092412010017500_bib54","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1177\/1066896908315812","article-title":"Clinical implications of idiopathic multicentric Castleman disease among Japanese: a report of 28 cases","volume":"16","author":"Kojima","year":"2008","journal-title":"Int J Surg Pathol"},{"issue":"12","key":"2024092412010017500_bib55","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1136\/jcp.2010.082958","article-title":"Multicentric Castleman's disease with abundant IgG4-positive cells: a clinical and pathological analysis of six cases","volume":"63","author":"Sato","year":"2010","journal-title":"J\u00a0Clin Pathol"},{"issue":"7","key":"2024092412010017500_bib56","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1111\/his.13186","article-title":"Comparison of clinical and pathological features of lung lesions of systemic IgG4-related disease and idiopathic multicentric Castleman's disease","volume":"70","author":"Terasaki","year":"2017","journal-title":"Histopathology"},{"issue":"1","key":"2024092412010017500_bib57","doi-asserted-by":"crossref","first-page":"20122","DOI":"10.7448\/IAS.18.1.20122","article-title":"Characteristics and survival for HIV-associated multicentric Castleman disease in Malawi","volume":"18","author":"Gopal","year":"2015","journal-title":"J\u00a0Int AIDS Soc"},{"issue":"2","key":"2024092412010017500_bib58","doi-asserted-by":"crossref","first-page":"244","DOI":"10.4103\/0377-4929.64335","article-title":"Castleman's disease \u2013 hyaline vascular type \u2013 clinical, cytological and histological features with review of literature","volume":"53","author":"Ghosh","year":"2010","journal-title":"Indian J Pathol Microbiol"},{"issue":"4","key":"2024092412010017500_bib59","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3346\/jkms.2000.15.4.393","article-title":"Clinicopathologic study of Castleman's disease in Korea","volume":"15","author":"Kim","year":"2000","journal-title":"J\u00a0Korean Med Sci"},{"issue":"4","key":"2024092412010017500_bib60","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/qjmed\/95.4.211","article-title":"Unicentric Castleman's disease complicated by systemic AA amyloidosis: a curable disease","volume":"95","author":"Lachmann","year":"2002","journal-title":"QJM"},{"issue":"3","key":"2024092412010017500_bib61","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/(SICI)1097-0142(19990201)85:3<706::AID-CNCR21>3.0.CO;2-7","article-title":"The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature","volume":"85","author":"Bowne","year":"1999","journal-title":"Cancer"},{"key":"2024092412010017500_bib62","unstructured":"UNAIDS\n          . Core epidemiology slides. 2023. Accessed 17 January 2024. https:\/\/www.unaids.org\/en\/resources\/documents\/2023\/core-epidemiology-slides."},{"issue":"1","key":"2024092412010017500_bib63","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.hoc.2017.09.008","article-title":"Treatment of idiopathic Castleman disease","volume":"32","author":"van Rhee","year":"2018","journal-title":"Hematol Oncol Clin North Am"},{"issue":"10","key":"2024092412010017500_bib64","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1038\/s41375-022-01690-2","article-title":"Organ dysfunction, thrombotic events and malignancies in patients with idiopathic multicentric Castleman disease: a population-level US health claims analysis","volume":"36","author":"Mukherjee","year":"2022","journal-title":"Leukemia"},{"issue":"2","key":"2024092412010017500_bib65","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/ajh.24242","article-title":"Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease","volume":"91","author":"Iwaki","year":"2016","journal-title":"Am J Hematol"},{"issue":"10","key":"2024092412010017500_bib66","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/ajh.26292","article-title":"Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease","volume":"96","author":"Nishimora","year":"2021","journal-title":"Am J Hematol"},{"issue":"9","key":"2024092412010017500_bib67","first-page":"4227","article-title":"Clinical characteristics and outcomes of Castleman disease: a multicenter Consortium study of 428 patients with 15-year follow-up","volume":"12","author":"Liu","year":"2022","journal-title":"Am J Cancer Res"},{"key":"2024092412010017500_bib68","first-page":"100720","article-title":"A\u00a0national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria","volume":"34","author":"Zhang","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"key":"2024092412010017500_bib69","doi-asserted-by":"crossref","first-page":"102192","DOI":"10.1016\/j.eclinm.2023.102192","article-title":"Symptom burden in patients with idiopathic multicentric Castleman disease and its impact on daily life: an international patient and caregiver survey","volume":"64","author":"Mukherjee","year":"2023","journal-title":"eClinicalMedicine"},{"issue":"12","key":"2024092412010017500_bib70","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.4065\/75.12.1284","article-title":"Publication bias: a brief review for clinicians","volume":"75","author":"Montori","year":"2000","journal-title":"Mayo Clin Proc"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/18\/4924\/2243771\/blooda_adv-2024-013548-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/18\/4924\/2243771\/blooda_adv-2024-013548-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T09:37:09Z","timestamp":1727170629000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/18\/4924\/516929\/The-clinical-picture-of-Castleman-disease-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,16]]},"references-count":70,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2024,9,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013548","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,16]]}}}